LRMR Stock Forecast & Price Target

Larimar Therapeutics is viewed positively because nomlabofusp targets the root cause of Friedreich’s ataxia by restoring frataxin, a mechanism that could make it the first disease-modifying therapy in a condition with no current cure. The clinical package is encouraging, with open-label data showing sustained biomarker correction and functional gains, including 82% of patients reaching asymptomatic-carrier skin frataxin levels at six months, 100% at one year, and a 2.6-point mFARS advantage versus FACOMS at one year. Financially, the company ended 1Q26 with $200.4M in cash, cash equivalents, and marketable securities, and its runway into 2Q27 appears sufficient to support the remaining 2H26 rolling BLA modules and planned 3Q26 Phase 3 initiation.

Larimar Therapeutics is highly exposed to regulatory and clinical risk because accelerated approval may still require additional data, longer studies, or tighter label conditions that could weaken market adoption. Its outlook is also pressured by commercial and competitive uncertainty, as it has little diversification beyond nomlabofusp while Biogen’s Skyclarys is already marketed for FA and other gene therapies are advancing. Financially, the company is likely to need additional external funding to keep its development platform moving, and any inability to access capital could delay or terminate programs, making the stock vulnerable to single-product setbacks or safety issues.